Network and Infrastructure Support for Development of Interdisciplinary Aging Research

For adults aged 40 to 75 years, randomized trials provide conclusive evidence that statins reduce the risk of initial and secondary cardiovascular disease (CVD) events. However, there is limited evidence that statins reduce CVD events in individuals over the age of 75 who do not have clinically recognized CVD, and older adults may be at greater risk of adverse effects from statins. It is important for statin treatment of this age group to be rigorously evaluated in a randomized clinical trial. The primary objective of this pilot study is to understand recent patterns of statin use and the feasibility of conducting a possible trial on the net effects of statins in adults more than 75 years old without clinical CVD.

0